p53 protein and vimentin in invasive ductal NOS breast carcinoma--relationship with survival and sites of metastases.
暂无分享,去创建一个
[1] S. Syrjänen,et al. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis , 1993, International journal of cancer.
[2] K. Weber,et al. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. , 1993, The American journal of pathology.
[3] W. McGuire,et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.
[4] I. Ellis,et al. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. , 1992, British Journal of Cancer.
[5] T. Visakorpi,et al. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. , 1992, Journal of the National Cancer Institute.
[6] J. Bartek,et al. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.
[7] E. Kawasaki,et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.
[8] Robert Clarke,et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines , 1992, Journal of cellular physiology.
[9] J. Bartek,et al. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. , 1992, Journal of cell science.
[10] A. Harris,et al. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. , 1991, Oncogene.
[11] T. Visakorpi,et al. Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.
[12] D. Lane,et al. Expression of p53 protein in infiltrating and in‐situ breast carcinomas , 1991, The Journal of pathology.
[13] S. Hirohashi,et al. Nuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer , 1991, Japanese journal of cancer research : Gann.
[14] B. Angus,et al. p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study , 1991, The Journal of pathology.
[15] G. Striker,et al. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. , 1990, The American journal of pathology.
[16] O. Petersen,et al. Regulation of vimentin expression in cultured human mammary epithelial cells. , 1990, Differentiation; research in biological diversity.
[17] K. Weber,et al. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. , 1990, The American journal of pathology.
[18] D. Lane,et al. p53: oncogene or anti-oncogene? , 1990, Genes & development.
[19] A S Leong,et al. Vimentin—a new prognostic parameter in breast carcinoma? , 1989, The Journal of pathology.
[20] A. Leong,et al. Co‐expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium , 1989, The Journal of pathology.
[21] K. Zedeler,et al. Histological grade and steroid receptor content of primary breast cancer--impact on prognosis and possible modes of action. , 1988, British Journal of Cancer.
[22] F. Rilke,et al. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. , 1988, British Journal of Cancer.
[23] Mark R. Segal,et al. Regression Trees for Censored Data , 1988 .
[24] J. Gerdes,et al. Growth Fraction as Determined in Cytologic Specimens of Breast Carcinomas: A Study with the Monoclonal Antibody Ki-67 , 1988 .
[25] U. Helmchen,et al. Coexpression of keratin and vimentin in damaged and regenerating tubular epithelia of the kidney. , 1987, The American journal of pathology.
[26] N. Azumi,et al. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. , 1987, American journal of clinical pathology.
[27] G M Clark,et al. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] L. Kaczmarek,et al. Coding sequence and growth regulation of the human vimentin gene , 1986, Molecular and cellular biology.
[29] W. Drobyski,et al. Estrogen receptors and the pattern of relapse in breast cancer. , 1984, Archives of internal medicine.
[30] K. Weber,et al. Monoclonal antibodies specific for vimentin. , 1984, European journal of cell biology.
[31] N. Connell,et al. Regulation of the cytoskeleton in mesothelial cells: Reversible loss of keratin and increase in vimentin during rapid growth in culture , 1983, Cell.
[32] R. Blamey,et al. Oestrogen-receptor status and sites of metastasis in breast cancer. , 1981, British Journal of Cancer.
[33] R. Rubens,et al. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. , 1981, European journal of cancer.
[34] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[35] H. Potter,et al. Estrogen Receptor and Natural Course of Breast Cancer , 1976, Annals of surgery.
[36] H. Bloom,et al. Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.